Blog
    Regulatory UpdateFor PhysiciansJuly 11, 2026

    FDA Compounding Status and Peptide Safety Signals

    Review FDA regulatory statuses for BPC-157 and other Category 2 peptides, plus postmarketing safety signals for GLP-1 RAs including pancreatitis and NAION.

    Clinical Question

    What is the current FDA regulatory status of commonly used peptides, and what safety signals have been identified through clinical trials and postmarketing surveillance?

    Evidence Snapshot

    • Regulatory Statuses: BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, and GHRP-2 are currently NOT FDA-approved drugs.
    • Compounding Restrictions: All listed peptides were designated as Category 2 bulk substances as of September 2023, indicating significant safety risks or lack of safety data, making them ineligible for routine 503A/503B compounding.
    • Safety Signals: Strong and emerging signals for GLP-1 agonists include gastrointestinal obstruction, delayed gastric emptying, acute pancreatitis, nonarteritic anterior ischemic optic neuropathy (NAION), and pulmonary aspiration.
    • Clinical Outcomes: Phase III data for approved GLP-1 RAs show weight loss ranging from 14.9% to 22.5% and a 20% reduction in Major Adverse Cardiovascular Events (MACE).

    What the Research Shows

    Evidence regarding these substances is divided between FDA-approved clinical trials for metabolic peptides and regulatory restrictions for non-approved compounds.

    Regulatory and Compounding Status As of March 2026, the FDA identifies several peptides as Category 2 bulk substances under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. BPC-157 is noted for significant safety risks, particularly regarding immunogenicity and a lack of safety data. Thymosin Alpha-1, despite being approved in over 35 countries as Zadaxin, remains non-FDA-approved and was removed from Category 2 pending advisory review in September 2024, though it remains a substance of concern. Similarly, TB-500 is cited for immunogenicity risks and a lack of human exposure data.

    Several compounds, including AOD-9604, CJC-1295, Ipamorelin, and Selank, had their nominations withdrawn or removed from the compounding list in September 2024. For CJC-1295, the FDA specifically cited safety issues such as increased heart rate. Warning letters have been issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (2020) regarding several of these substances.

    Clinical Outcomes of Approved/Investigational Peptides Clinical trial evidence for approved GLP-1 RAs demonstrates significant efficacy. The STEP 1 trial (NCT03548935) reported 14.9% weight loss with Semaglutide, while the SELECT trial (NCT03574597) showed a 20% reduction in MACE. Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial (NCT04184622) and was superior to semaglutide in the SURMOUNT-5 trial. Retatrutide, currently in Phase III (TRIUMPH-3), showed 24.2% weight loss at 12mg in Phase II.

    Conversely, trials for Thymosin Alpha-1 in sepsis (NCT02867267) were negative, showing no mortality reduction.

    Safety Signal Analysis FAERS data through 2023 for Semaglutide includes 187,757 GLP-1 RA reports. Strong signals exist for nausea, vomiting, and delayed gastric emptying. Moderate signals for acute pancreatitis and cholelithiasis (gallbladder inflammation) are noted in the drug labeling. Postmarketing surveillance has identified emerging signals for intestinal obstruction/ileus and pulmonary aspiration. As of January 2025, NAION (96 cases through December 2024) is under EMA review. The FDA requires monitoring for suicidal ideation, though data currently do not support a risk higher than the background rate.

    Mechanism

    (Mechanism data not provided in the source records for the listed regulatory statuses or safety signals.)

    Limitations of the Evidence

    There is a notable divide in the quality of evidence across these substances. Semaglutide and Tirzepatide are supported by large-scale Phase III human clinical trials with published results. In contrast, BPC-157 and TB-500 lack comprehensive human exposure data, as noted in their FDA regulatory status. Furthermore, several peptides including Selank and Semax are approved in Russia but lack FDA approval, potentially limiting the availability of Western clinical trial data. FAERS data represents spontaneous reporting and cannot definitively establish causality for emerging signals like NAION or pulmonary aspiration.

    Clinical Takeaway

    Physicians should note that BPC-157, TB-500, Thymosin Alpha-1, and several other peptides are not FDA-approved and are currently categorized by the FDA as having significant safety risks (such as immunogenicity) or insufficient safety data, precluding their routine use in compounding. For approved metabolic peptides, clinical trials confirm significant weight loss and cardiovascular benefits, but evolving safety profiles require vigilance regarding gastrointestinal obstruction and perioperative pulmonary aspiration risks.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2)
    • FAERS Safety Signal Database (Semaglutide)
    • Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.